The recent dramatic success in the treatment of testicular cancer is due to advances in patient management involving computerised tomography, effective combination chemotherapy, and accurate measurement of the biochemical markers afoetoprotein (a-FP) and ,B subunit of human gonadotrophin (#HCG) (Ellis & Sikora, 1984) .
These two proteins are abnormally high in the serum of most teratoma patients where they provide a reliable index of disease presence. However, some 30% of teratoma patients do not exhibit a raised aFP or PHCG at diagnosis and here these markers cannot be used to monitor disease status (Coppack et al., 1983) . In seminoma, no reliable biochemical marker is known (although placental alkaline phosphate is currently being investigated). We have studied patients with testicular tumours and compared standard markers with a new haemagglutination test for tumour presence.
B5 is a rat monoclonal antibody (IgG) which has been found to agglutinate erythrocytes from patients with malignant disease (Metcalfe et al., 1984) . The incidence of B5 positivity is 80% in cancer patients which, when compared to a normal incidence of 20% in control groups, implies that people who are normally B5 negative become B5 positive if they develop cancer. B5 haemagglutination was tested in 79 patients attending the testicular tumour clinic over a period of 16 months using methods reported previously (Metcalfe et al., 1984) . The overall results are given in Table I . We found that (a) both teratoma and seminoma patients are B5 positive; (b) individual patients revert to a B5 negative state when the tumour is successfully removed; (c) some patients remain B5 positive, although clinically without active disease: in most cases we anticipate that this group represents those individuals who are normally B5 positive, although the possibility of persistent disease should be considered, as was found in two patients in this study; and (d) the timing of the change in the B5 status after tumour removal relates -as expected -to the erythrocyte life span.
It is interesting to consider in more detail those patients who were monitored over a prolonged period of up to two years in this study. In Figure  la it can be seen that three seminoma patients, negative for aFP and flHCG were B5 positive and subsequently recovered a B5 negative status at similar rates, plateauing about one year after removal of the primary tumour. A similar time course was followed by two of the three teratoma patients represented in Figure lb: one of these had very high ,BHCG and aFP levels at diagnosis, and also showed a strong positivity with B5; another patient was first monitored with B5 three months after a second course of chemotherapy for recurrent tumour. This recurrence was associated with abnormal levels of flHCG and aFP, and with B5 positivity. The third patient in Figure lb switched to B5 negative within 6 months; at presentation this patient was asymptomatic, was negative for PiHCG and aFP, and had a very small tumour removed. Thus, for this patient, B5 was clearly a sensitive indicator of tumour presence. In Figure Ic two further patients with a more complex case history of teratoma are shown, both of whom showed a rapid recovery of normal ,BHCG and aFP levels after surgery. One had had invasive disease with lung metastases and showed a prolonged B5 positive status followed by an irregular change towards a negative status as the disease responded to treatment and regressed. The second patient showed no shift towards a B5 negative state, although clinically assessed as being free from disease. After a year this patient was considered to be a "false positive" B5. However, at 17 months the patient was discovered to have residual disease, although his aFP and fHCG levels remained aOne patient in this study was B5 negative when tested soon after surgery: his fiHCG and aFP markers had been markedly raised. This patient had required blood transfusions, a factor which might explain this initial B5 negative result, since the patient became B5 positive at 3 months, before reverting to a B5 negative status at 7 months. Initial observations on 13 of these patients have been reported elsewhere (Metcalfe et al., 1984) .
diagnosis and B5 appears to be a sensitive indicator of residual tumour/recurrence.
In conclusion, we feel that the simple B5 test is a worthwhile addition to the monitoring protocol for testicular tumour patients, especially where aFP and ,BHCG levels remain normal. In addition, current trials of surveillance alone in early stage seminoma would benefit considerably from an efficient marker such as B5. 
